Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 180-184, 2010.
Article
в En
| WPRIM
| ID: wpr-209006
Ответственная библиотека:
WPRO
ABSTRACT
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
Key words
Полный текст:
1
База данных:
WPRIM
Основная тема:
Appointments and Schedules
/
Pyrroles
/
Carcinoma, Renal Cell
/
Renal Dialysis
/
Disease-Free Survival
/
Indoles
Пределы темы:
Humans
Язык:
En
Журнал:
Cancer Research and Treatment
Год:
2010
Тип:
Article